Get ready for SABCS25 with LucidQuest’s concise preview of the sessions and themes shaping breast cancer research this year. We highlight key clinical developments and emerging AI and ML tools to help you plan what to follow at the meeting.
📅 Build your schedule around the topics that interest you. 📥 Download the SABCS 2025_Preview_by_LucidQuest
Dive deeper
Key Topics From SABCS 2025 Scientific Presentations
Triple-Negative Breast Cancer:
• Chemo combinations plus Ki67, TILs, and immune signatures aim to personalize care and improve pCR and survival.
Carboplatin in TNBC:
• Carboplatin improves pCR and EFS in early and advanced TNBC, without OS benefit; immune signatures remain prognostic for EFS.
HER2-Low and Ultralow:
• HER3-directed ADCs and T-DXd continue shaping care. Sequential topo-I ADCs show cross-resistance, highlighting the need for predictive biomarkers.
T-DXd in HER2-Low MBC:
• DESTINY-Breast04/07 demonstrate strong efficacy, with vigilant ILD monitoring remaining essential.
HER2-Positive Advanced Breast Cancer:
• DP303c is expected to outperform T-DM1, improving PFS and ORR with manageable safety.
Endocrine–HER2 Strategy Optimization:
• ALTTO supports aromatase inhibitors—with OFS for premenopausal patients—as preferred partners with anti-HER2 therapy.
HR+/HER2– PALVEN Triplet:
• Letrozole, palbociclib, and venetoclax achieved 93% CBR and 29.2-month PFS with manageable toxicity.
Artificial intelligence and Machine Learning at SABCS 2025
Mammography Risk Prediction:
• AI improves risk prediction in benign breast disease, supporting earlier targeted prevention.
Dense Breast Screening:
• Generative AI analyzes tumor-derived oncRNAs for non-invasive detection in dense breast tissue.
FES-PET Response Prediction:
• AI integrates imaging and clinical data to forecast endocrine therapy benefit in ER+/HER2– metastatic disease.
Digital Pathology in HER2-Positive Disease:
• AI quantifies spatial sTILs to guide targeted therapy selection.
Digital Twins for TNBC:
• Multi-modal AI predicts pCR to neoadjuvant therapy, supporting personalized regimens and reduced toxicity.
Cost-Effective Prognostics:
• Models like MMAI and RlapsRisk BC estimate distant-metastasis risk as cost-effective alternatives to genomic assays.
ILC Histology and TME Profiling:
• AI maps tumor microenvironment patterns to identify late-recurrence risk, supporting extended endocrine therapy decisions.
📅 Build your schedule around the topics that interest you.
📥 Download the SABCS 2025_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.